e-therapeutics 관리
관리 기준 확인 4/4
e-therapeutics' CEO is Ahmad Mortazavi, appointed in Oct 2020, has a tenure of 3.58 years. total yearly compensation is £270.00K, comprised of 77% salary and 23% bonuses, including company stock and options. directly owns 8.72% of the company’s shares, worth £4.58M. The average tenure of the management team and the board of directors is 3.3 years and 4.1 years respectively.
주요 정보
Ahmad Mortazavi
최고 경영자
UK£270.0k
총 보상
| CEO 급여 비율 | 77.0% |
| CEO 임기 | 3.6yrs |
| CEO 소유권 | 8.7% |
| 경영진 평균 재임 기간 | 3.3yrs |
| 이사회 평균 재임 기간 | 4.1yrs |
최근 관리 업데이트
Recent updates
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Jan 05
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Sep 13e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Mar 27We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Jul 07We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn
Oct 28Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?
Mar 21We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Feb 14Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?
Jan 10
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
Dec 06CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jul 31 2023 | n/a | n/a | -UK£10m |
| Apr 30 2023 | n/a | n/a | -UK£9m |
| Jan 31 2023 | UK£270k | UK£208k | -UK£8m |
| Oct 31 2022 | n/a | n/a | -UK£9m |
| Jul 31 2022 | n/a | n/a | -UK£9m |
| Apr 30 2022 | n/a | n/a | -UK£9m |
| Jan 31 2022 | UK£348k | UK£200k | -UK£8m |
| Oct 31 2021 | n/a | n/a | -UK£6m |
| Jul 31 2021 | n/a | n/a | -UK£4m |
| Apr 30 2021 | n/a | n/a | -UK£4m |
| Jan 31 2021 | UK£136k | UK£107k | -UK£4m |
보상 대 시장: Ahmad's total compensation ($USD338.12K) is about average for companies of similar size in the UK market ($USD347.41K).
보상과 수익: Ahmad's compensation has been consistent with company performance over the past year.
CEO
Ahmad Mortazavi (52 yo)
3.6yrs
테뉴어
UK£270,000
보상
Mr. Ahmad Ali Mortazavi serves as Chief Executive Officer at e-Therapeutics plc since October 2020 and had been its an Executive Chairman since February 10, 2020 until March 01, 2021. Mr. Mortazavi served...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 3.6yrs | UK£270.00k | 8.72% £ 4.6m | |
| CFO, Director of Finance & Operations and Company Secretary | 1.5yrs | 데이터 없음 | 데이터 없음 | |
| Chief Operating & Business Officer | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Chief Scientific Officer | 9.4yrs | 데이터 없음 | 데이터 없음 | |
| Head of Software Engineering | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Head of Therapeutic Discovery | 3.3yrs | 데이터 없음 | 데이터 없음 |
3.3yrs
평균 재임 기간
경험이 풍부한 관리: ETX's management team is considered experienced (3.3 years average tenure).
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | UK£270.00k | 8.72% £ 4.6m | |
| Independent Non-Executive Chairman | 8.6yrs | UK£55.00k | 0.22% £ 116.5k | |
| Independent Non-Executive Director | 4.3yrs | UK£120.00k | 0.086% £ 45.0k | |
| Chair of Scientific Advisory Board | 4yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.7yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.7yrs | 데이터 없음 | 데이터 없음 |
4.1yrs
평균 재임 기간
68yo
평균 연령
경험이 풍부한 이사회: ETX's board of directors are considered experienced (4.1 years average tenure).